TY - JOUR
T1 - HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates
AU - Wang, Luoquan
AU - Vuolo, Magalis
AU - Suhrland, Mark J.
AU - Schlesinger, Kathie
PY - 2006
Y1 - 2006
N2 - Objective: To investigate immunohistochemical staining of hepatocyte paraffin-1 (HepPar1), α-fetoprotein (AFP), polyclonal carcinoembryonic antigen (pCEA), monoclonal CEA (mCEA), MOC-31 and CD10 for differential diagnosis of hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) on fine needle aspiration biopsy (FNAB). Study Design: Fifty-one archival, paraffin-embedded FNAB cell blocks, representing 18 HCCs and 33 MAs, were immunostained with antibodies for AFP CD10, pCEA, mCEA, HepPar1 and MOC-31. Results HepPar1, AFP, canalicular pCEA and CD10 were positive in 78% (14 of 18), 28% (5 of 18), 72% (13 of 18) and 35% (6 of 17) of cases of HCC, respectively. The 33 MAs were negative for immunostaining of the above antibodies except for one AFP-positive MA. Ninety-seven percent (31 of 32) of the MAs and 6% (1 of 17) of the HCCs were positive for MOC-31. Monoclonal CEA was immunoreactive on 82% (27 of 33) of the MAs and negative on all the HCCs. Conclusion: HepPar1 was the most sensitive marker for HCC, followed by canalicular staining for pCEA. For MA, MOC-31 was the most sensitive marker; mCEA was slightly less sensitive but more specific. We suggest using HepPar1, pCEA, CD10, MOC-31 and mCEA as a panel for distinguishing HCC from MA in liver FNAB.
AB - Objective: To investigate immunohistochemical staining of hepatocyte paraffin-1 (HepPar1), α-fetoprotein (AFP), polyclonal carcinoembryonic antigen (pCEA), monoclonal CEA (mCEA), MOC-31 and CD10 for differential diagnosis of hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) on fine needle aspiration biopsy (FNAB). Study Design: Fifty-one archival, paraffin-embedded FNAB cell blocks, representing 18 HCCs and 33 MAs, were immunostained with antibodies for AFP CD10, pCEA, mCEA, HepPar1 and MOC-31. Results HepPar1, AFP, canalicular pCEA and CD10 were positive in 78% (14 of 18), 28% (5 of 18), 72% (13 of 18) and 35% (6 of 17) of cases of HCC, respectively. The 33 MAs were negative for immunostaining of the above antibodies except for one AFP-positive MA. Ninety-seven percent (31 of 32) of the MAs and 6% (1 of 17) of the HCCs were positive for MOC-31. Monoclonal CEA was immunoreactive on 82% (27 of 33) of the MAs and negative on all the HCCs. Conclusion: HepPar1 was the most sensitive marker for HCC, followed by canalicular staining for pCEA. For MA, MOC-31 was the most sensitive marker; mCEA was slightly less sensitive but more specific. We suggest using HepPar1, pCEA, CD10, MOC-31 and mCEA as a panel for distinguishing HCC from MA in liver FNAB.
KW - Adenocarcinoma
KW - Hepatocellular carcinoma
KW - Immunohistochemistry
KW - Liver cancer
UR - http://www.scopus.com/inward/record.url?scp=33744784568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33744784568&partnerID=8YFLogxK
U2 - 10.1159/000325951
DO - 10.1159/000325951
M3 - Article
C2 - 16780018
AN - SCOPUS:33744784568
SN - 0001-5547
VL - 50
SP - 257
EP - 262
JO - Acta cytologica
JF - Acta cytologica
IS - 3
ER -